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http://www.biomedcentral.com/1471-2180/14/212RESEARCH ARTICLE Open AccessBacteriophage as effective decolonising agent for
elimination of MRSA from anterior nares of BALB/c
mice
Sanjay Chhibber*, Paridhi Gupta† and Sandeep Kaur†Abstract
Background: Nasal carriers not only pose serious threat to themselves but also to the community by playing an
active role in the dissemination of serious and life threatening S. aureus especially MRSA strains. The present study
focuses on the use of broad spectrum lytic phage as decolonising agent. In addition, the combined use of lytic
phage with mupirocin has also been investigated as an effective decolonising regimen. The effect of phage on the
adherence, invasion and cytotoxic effect of MRSA strains on nasal epithelial cells was studied in an ex-vivo model of
cultured murine nasal epithelial cells. This was followed by demonstration of therapeutic potential of phage along
with mupirocin in decolonising the nares of BALB/c mice using a nasal model of MRSA colonisation.
Results: Phage was able to significantly reduce the in vitro adherence, invasion and cytotoxicity of MRSA 43300 as
well as other clinical MRSA strains on murine nasal epithelial cells as compared to untreated control. Also, the
frequency of emergence of spontaneous mutants decreased to negligible levels when both the agents (phage and
mupirocin) were used together.
Conclusion: Phage MR-10, given along with mupirocin showed an additive effect and the combination was able to
effectively eradicate the colonising MRSA population from the nares of mice by day 5.
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Approximately 20% of healthy adults are persistent nasal
carriers of S. aureus and 60% harbour it intermittently.
Such carriers have been shown to participate in the epi-
demiology and pathogenesis of S. aureus infections and
are a potential source of outbreaks especially in hospital
settings [1,2]. Nasal carriers are at an increased risk of
acquiring surgical site infections, foreign body infections
and bacteremias [3,4]. Although nasal colonisation with
MRSA is low but such carriers are a major threat factor
for themselves (through auto-infection/endogenous source)
as well as can disseminate these highly resistant strains
that pose serious difficulty in treatment thereafter.
The current treatment strategies for nasal decolonisation
rely on the use of topical antibiotics such as bacitracin, fusi-
dic acid, ciprofloxacin, rifampicin [5]. However, emergence* Correspondence: sanjaychhibber8@gmail.com
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unless otherwise stated.of resistant strains has led to treatment failures. Mupirocin
is another potent anti-MRSA agent which has been found
to be effective in decolonising the nares. Long term studies
have however, shown that there is an initial clearance of
bacteria from nares following mupirocin treatment but
re-colonization takes place after 3 months [6,7]. The
rapid emergence of resistance to mupirocin therefore calls
for search for alternative options. Phage therapy has been
shown to be a potential alternative treatment for treating
various S. aureus infections [8-13]. Hence, an alternative
or supplement to antibiotic therapy, is the use of bacterial
viruses (phage/bacteriophage) to target MRSA colonisation
in the anterior nares of the affected population.
However, there is comparatively limited work published
on the use of phages as nasal decolonising agents as
compared to their proven therapeutic potential in other
infections. Moreover, the combined application of phage
and antibiotic in eliminating the nasal load of S. aureus has
not been looked into earlier studies. Combination therapy
(use of two different agents) represents an attractive optional Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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gence of resistant mutants [13,14].
Methods
Ethical statement
The experimental protocols were approved by the Institu-
tional Animal Ethics Committee of the Panjab University,
Chandigarh, India and performed in accordance with
the guidelines of Committee for the Purpose of Control
and Supervision of Experiments on Animals (CPCSEA),
Government of India, on animal experimentation. All
efforts were made to minimize the suffering of animals.
Bacterial strains and phage used
S. aureus ATCC 43300(MRSA) and S. aureus ATCC
29213(MSSA) from ATCC, Mannasse, USA were used in
this study. These two strains were used to study the
bacterial adherence, invasion and cytotoxicity on cultured
murine epithelial cells. However, S. aureus 43300 was
used to establish the nasal colonisation in BALB/c mice.
Clinical isolates of S. aureus were procured from Post-
graduate Institute of Medical Education and Research
(PGIMER), Chandigarh, India. The strains were isolated
from clinical specimens (nasal screening swabs, blood,
pus, soft tissue, wound swabs, respiratory samples and
body fluids) collected from both in-patient and as out-
patient subjects. The strains were identified on the basis of
Gram reaction, growth on mannitol salt agar (MSA), cata-
lase activity, and coagulase test. Methicillin resistance was
determined using cefoxitin disk on Mueller-Hinton agar
(Oxoid) followed by determination of MICs of oxacillin for
these strains as recommended by Clinical and Laboratory
Standards Institute (CLSI) [15]. A total of thirty four MRSA
isolates were selected, numbered sequentially as MRSA 01
to MRSA 34 (clearly depicting their source) and stored in
glycerol at −80°C. These strains were used for determining
the lytic spectrum/host range of the isolated phage.
S. aureus specific bacteriophage, MR-10, which had been
isolated and characterized in our laboratory was used in the
present study [13]. This phage was selected as it showed a
broad host range against four standard strains of S. aureus
[S. aureus ATCC 43300(MRSA), S. aureus ATCC 29213
(MSSA), S. aureus ATCC 25923(MSSA) and S. aureus
ATCC 33591(MRSA)] as well as was effective against 32/34
clinical MRSA isolates (data depicting the host range of
MR-10 is included in Additional file 1: Table S1).
Animals used
BALB/c female mice, 4–6 weeks old weighing 20–25 g
were used in this study. The animals were obtained from
Central Animal House, Panjab University, Chandigarh.
The animals were kept in well aerated rooms and given
antibiotic free diet (Hindustan Lever, Mumbai) and water
ad libitum.Isolation and culturing of murine nasal epithelial cells (NEC)
This was performed according to the method of Grubb
et al. [16]. Nasal septum was dissected from five mice
and washed with Dulbecco modified Eagles Medium
(DMEM) with 100 μg/ml streptomycin. The septum was
homogenized and centrifuged at 2000 rpm for 10 min.
The nasal tissue was re-suspended in dissociation medium
(10 mM HEPES- streptomycin-DMEM) overnight at 4°C.
Next day, the tissue suspension was again centrifuged and
suspended in isolation media (145 mM NaCl, 4.5 mM
KCl, 10 mM glucose, 10 mM HEPES) and kept at 37°C for
2 hours. The tissue was then teased gently using 26G nee-
dle to form single cell preparation. The cell suspension
was passed through cell strainer (100 μ Nylon; BD) and
given washings thrice and finally suspended in DMEM.
Cells were viewed under phase contrast (Olympus, 40×)
and counted using trypan blue staining to determine cell
viability in a haemocytometer.1 ml of 105 cells/ml was
seeded in each well of 12 well plate and incubated at 37°C
in 5%CO2. The cells were monitored each day for cell
density and increase in cell size, using crystal violet stain-
ing of smears prepared from the cells.
Preparation of NEC and bacteria inoculum for adherence,
invasion and cytotoxicity assay
Cells obtained on day 5 of culturing were aspirated from
their respective wells and transferred to microfuge tube.
Cells were centrifuged at 1800 rpm for 10 min at 4°C. The
pellet so obtained was washed twice with PBS (pH 7.2)
and finally re-suspended in DMEM. Cells were stained
using trypan blue and counted in haemocytometer. An
average of 106 nasal cells/ml were used for adherence
assay. S. aureus ATCC 43300(MRSA), S. aureus ATCC
29213(MSSA) and five different clinical MRSA isolates
(for which phage MR-10 showed activity) were used in the
adherence, invasion and cytotoxicity assay. Single colony
of bacteria was inoculated in sterile BHI broth and
incubated overnight. Next day, cells were harvested by
centrifugation at 10,000 rpm for 15 minutes at 4°C. The
pellet so obtained was washed twice with sterile normal
saline (0.85%). The final pellet obtained was suspended
in normal saline and its O.D(600 nm) adjusted so as to
obtain cell density corresponding to 108 CFU/ml. This
was confirmed by plating on nutrient agar plates.
Adherence assay
Washed nasal epithelial cells, re-suspended in DMEM
were seeded in 12 well plate. Bacterial suspension (corre-
sponding to 1 × 108 CFU/ml) was added to obtain a ratio
of 10:1(Bacteria : nasal epithelial cells). Following 3 h of
incubation at 37°C in 5% CO2, the inoculum was removed
and the epithelial cells were washed thrice with PBS by
centrifugation at 1800 rpm for 10 min at 4°C to remove
non associated bacteria. (Note: Supernatant after each
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wash, there was complete removal of the non-adhered
bacterial cells). The cells were then treated with lysis
solution (0.025% trypsin and 1% tween 20 in PBS) for
30 min at 37°C. Total number of associated bacteria (T)
(adherent and invaded) was assessed by plating suitable
dilutions of the cell suspension on nutrient agar plates.
The final results were expressed as% adherence. Suitable
control containing only nasal epithelial cells with no
added bacteria was also processed in the same way to
check for sterility throughout the experiment.
Invasion assay
The gentamicin survival assay was performed as per the
method of El-Housseiny et al. [17] in order to determine
the number of invaded bacteria. After the addition of
bacteria (10:1) to the seeded NEC, the plate was incubated
for 3 h at 37°C in 5% CO2. It is essential to remove adher-
ent as well as extracellular bacteria in order to determine
the invaded population. For this, gentamicin solution was
added to all the wells at a concentration of 25 μg/ml and
the plate was incubated for 1 h at 37°C in 5% CO2 to kill
the extracellular bacteria (Note : this concentration was
based on the MIC value of gentamycin determined against
MRSA 43300 which was 16 μg/ml. In addition, after
treatment with 25 μg/ml of gentamycin for 1 hour, the
supernatant containing killed bacteria was plated out with
complete killing (no colonies on incubation) observed).
Finally, the epithelial cells were washed thrice with PBS
by centrifugation at 1800 rpm for 10 min at 4°C to remove
non associated bacteria. The cells were re-suspended in
DMEM and then treated with lysis solution (0.025% tryp-
sin and 1% tween 20 in PBS) for 30 minutes at 37°C in 5%
CO2. The cell suspension so obtained was suitably diluted
and plated on nutrient agar plates. This bacterial count so
obtained represented the number of invaded bacteria (I).
The difference between the total number of associated
bacteria (T) and the number of invaded bacteria (I) was
taken as number of adhered bacteria = (T-I) CFU/ml.
Results were expressed as % invasion and % adherence.
Cytotoxicity assay
To determine the cytotoxic effect of S. aureus cells on
NEC, (4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) reduction assay was performed as per
the method of Saliba et al. [18]. Washed nasal cells,
re-suspended in DMEM were seeded in 12 well plate.
After addition of bacteria (bacteria: NEC- 10:1), the
plate was incubated for adherence to occur. After 6 h
of incubation, gentamicin was added to the wells to
kill the extracellular bacteria. To the washed cells,
MTT was added (2 mg/ml in PBS) and incubated for
1 h at 37°C in 5% CO2. Supernatant was discarded and
cells were treated with 100 μl of absolute ethanol todissolve the formazan crystals and absorbance measured
at 540 nm. The same procedure was repeated at 24 and
48 hours. Suitable control wells containing only epithelial
cells without added bacteria were also processed in the
same way at all time points. The percentage cytotoxicity
was calculated using the following formula:
% Cytotoxicity ¼ ½1‐ A540of test well= A540of control wellð Þ
 100
Effect of phage on bacterial adhesion, invasion and
cytotoxicity on NEC
Washed nasal epithelial cells re-suspended in DMEM were
seeded in 12 well plate. Bacterial suspension (corresponding
to 1 × 108 CFU/ml) was added to nasal epithelial cells
(10:1). Following bacterial addition, phage was added at
MOI-1 and 10, and the plate was incubated for 3 h at 37°C
in 5% CO2. After incubation, the inoculum was removed
and the epithelial cells were washed thrice with PBS by
centrifugation at 1800 rpm for 10 min at 4°C to remove
non associated bacteria. The cells were re-suspended in
DMEM. The cells were then treated with lysis solution
(0.025% trypsin and 1% tween 20 in PBS) for 30 min at
37°C in 5% CO2. Total number of associated bacteria (T)
(adherent and invaded) was assessed by plating suitable
dilutions of the cell suspension on nutrient agar plates.
Similarly, for invasion assay, washed nasal epithelial cells
were incubated with the respective bacterial suspension
(corresponding to 1 × 108 CFU/ml) and phage was added
at MOI-1 and 10. The plate was incubated for 3 h at 37°C
in 5% CO2. This was followed by addition of gentamicin
solution (25 μg/ml) to kill the extracellular bacteria. The
epithelial cells were washed thrice with PBS to remove
non associated bacteria and phage. The cells were re-
suspended in DMEM, treated with lysis solution. The cell
suspension so obtained was suitably diluted and plated on
nutrient agar plates.
For cytotoxicity assay, washed nasal cells, re-suspended
in DMEM were seeded in 12 well plate. After addition of
bacteria (bacteria: NEC- 10:1), phage was added at MOI-1
and 10. The plate was incubated for different time intervals
(6 h, 24 h and 48 h) at 37°C in 5% CO2. After the comple-
tion of respective time interval, gentamicin was added to
the wells to kill the extracellular bacteria. After this step,
same procedure was repeated as described under cytotox-
icity assay.
Appearance of bacteriophage insensitive mutant (BIM)
and mupirocin resistant mutants
The frequency of spontaneous mutation in S. aureus
43300 on exposure to phage and mupirocin was deter-
mined. For BIM frequency, plaque assay was performed
using an overnight culture of S. aureus 43300 containing
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respectively. The plates were incubated overnight at
37°C. All resulting colonies were counted, and the BIM
frequency was determined by dividing the number of
surviving colonies by the original bacterial titer. Similarly,
spontaneous mutation frequency for mupirocin was
also determined at both 2 and 4 μg/ml according to the
method of O’Neill et al. [19] using cation adjusted Mueller
Hinton agar plates. The frequency of spontaneous muta-
tion was determined by dividing the number of surviving
colonies on selective plates by total number of colonies on
non-selective plates after 48 hours of incubation.
Frequency of appearance of resistant mutants in pres-
ence of both phage (MOI-10) and mupirocin together was
determined by performing the plaque assay on selective
plates with 2 and 4 μg/ml of mupirocin.
Antibiotic susceptibility of bacteria isolated from
murine nares
Three independent colonies were regularly isolated (data
shown in Additional file 1: Table S2) from the nares of
randomly selected male BALB/c mice in six independent
experiments. These were referred to as NS-1, NS-2 and
NS-3. For evaluating the bacterial load of S. aureus
43300 on different days post-colonisation in the murine
nasal colonisation model described below, a selective
media allowing the growth of only S. aureus 43300 with-
out interference from the nasal flora was needed. Hence,
nutrient agar plates with different concentrations of
ampicillin (4, 8, 16, 20 and 32 μg/ml) were prepared. All
the nasal isolates (NS-1, NS-2, NS-3, S. aureus 29213 as
well as S. aureus 43300) were spread plated respectively.
Nutrient agar plates with no antibiotic were used as
control. All the plates were incubated for 24 h at 37°C.
Next day, growth was observed on plates and the ampicil-
lin concentration showing complete inhibition of growth
(no colonies on selective plates) was noted. Ampicillin at a
concentration of ≥16 μg/ml completely inhibited the
growth of NS-1, NS-2 and NS-3 however MRSA 43300
growth was inhibited at 32 μg/ml. Hence, a dose of 20 μg/
ml ampicillin was selected to be added to nutrient agar for
preparing selective plates which allowed the growth of
MRSA 43300 colonies only with no interference from
nasal flora strains.
Nasal carriage model of S. aureus 43300
S. aureus 43300 was cultivated for 24 h at 37°C in brain
heart infusion broth. Next day, cells were pelleted and
washed twice with phosphate-buffered saline (PBS). Bac-
terial suspension prepared in PBS was adjusted at
600 nm so as to achieve a cell density corresponding to
a range of bacteria inoculums (105,106 and 107 CFU/ml).
The number of CFU/ml was confirmed by quantitative
plate count. Mice were grouped randomly into threegroups (N = 3) with twenty mice (n = 20) per group. For
intranasal instillation, a 50 μl inoculum of respective
bacterial dose was instilled into the nasal opening while
holding the mice upright. The mouse was held upright
for at least 2 minutes to allow the mice to take the
inoculum with minimum loss. After an interval of
48 hours, second dose of inoculum was again instilled
into the nares of mice in the same way as described
above. Four mice from each group were sacrificed on
day 2, 5, 7, 10 and 12 post inoculum administrations.
After disinfecting the nasal area with 70% alcohol, the
nasal tissue was dissected from each mouse and washed
twice in PBS (pH 7.2). The tissue was homogenized, and
dilutions of the homogenates were plated on nutrient
agar plates to evaluate total bacterial flora. The hom-
ogenate dilutions were also plated on nutrient agar
plates containing ampicillin (20 μg/ml) so as to check
the load of S. aureus 43300 colonised in the nasal tissue.
Phage and mupirocin protection studies
Therapeutic potential of bacteriophage, MR-10 alone as
well as in combination with mupirocin was evaluated for
its ability to reduce the nasal carriage in BALB/c mice.
Male BALB/c mice were used and randomly divided
into four groups (N = 4) with each group containing 20
mice each (n = 20). The infection and treatment sched-
ule is depicted in Figure 1.
Group 1: Mice were administered S. aureus 43300
(106 CFU/ml) intranasally
Group 2: Mice were administered S. aureus 43300, left
for a period of 48 hours to allow nasal colonisation
followed by intranasal administration of 50 μl of phage
(107 PFU/ml) given twice (at an interval of 24 hours).
Group 3: Mice were administered S. aureus 43300, left for
a period of 48 hours to allow nasal colonisation followed
by intranasal administration of 50 μl of mupirocin
(5 mg/kg dissolved in water; given once) the next day.
Group 4: Mice were administered S. aureus 43300, left
for a period of 48 hours to allow nasal colonisation
followed by intranasal administration of phage as well
as mupirocin (5 mg/kg) the next day.
The parameters used to monitor colonization included
a) Bacterial load (CFU/ml) in nares b) Phage counts in
nares c) Nasal myeloperoxidase (MPO) levels and e)
Histopathological examination
Nasal bacterial load
Four mice from each of group were taken and sacrificed
on day 2, 5, 7, 10, 12 post treatment by cervical dislocation.
The nasal region was wiped externally with 70% ethanol,
nose was removed along with nasal bone. The entire nasal
tissue was excised using sterile scissors and homogenized.
Figure 1 Schematic representation of the infection and treatment schedule followed for establishing nasal colonization model in BALB/c mice.
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agar containing 20 μg/ml of ampicillin to select S. aureus
43300 after overnight incubation at 37°C. Nasal homoge-
nates were also processed to determine the phage titer by
modified double layer agar method [20].
Myeloperoxidase (MPO) estimation
Mice from each group (same groups as those categorized
for phage protection studies with 20 animals per group)
were killed and their nasal tissue was excised and homo-
genised in 50 mM PBS (pH 7.4). Nasal samples were
processed for MPO determination as per the method of
Greenberger et al. [21]. The absorbance was read imme-
diately at 490 nm over a period of 4 minutes. MPO was
calculated as the change in optical density (O.D) x dilution
factor (D.F).
Histopathological examination
Extent of injury caused by S. aureus and healing of the
colonized mouse nose following therapy with phage or
antibiotic was assessed on the basis of histopathological
analysis of the injured and recovered nose according to
the method of Brans et al. [22]. The sections were
picked on separate slides, stained with hematoxylin and
eosin (Hi-Media, Mumbai) and the slides then examined
under a microscope to evaluate the extent of damage.
Statistical methods
The data is expressed as mean ± standard deviation of
replicated values where indicated. The statistical signifi-
cance of differences between groups was determined by
Student’s t-test (two groups),one-way ANOVA followedby a Tukey test using Sigma Stat, Graph pad prism
(Graph pad software, San Diego, CA). p value of less
than 0.05 and 0.01 was considered statistically significant
for a confidence interval of 95% and 99% respectively.
Results
The nasal epithelial cells were isolated from mouse nasal
tissue and cultured at 37°C in presence of 5% CO2.
Figure 2 depicts various stages of nasal epithelial cell (NEC)
maturation on different days. The cells were observed as
single cells at the time of isolation (Figure 2A and B).
Thereafter, there was an increase in their size and density
of the cells. Nucleus was clearly visible by day 2 and shape
of the cells changed throughout the time of observation
(Figure 2C and D). Day 3 onwards the cells differentiated
into different shapes ranging from oval to round shape cells
(Figure 2E and F). The cells obtained on day 5 (Figure 2G)
were chosen for adherence studies as significant increase in
size was attained by this time.
Since bacterial adherence is an essential step in the
colonisation process of an organism, hence the percentage
adherence of MRSA 43300 was studied using cultured
NEC. Bacteria was added in order to obtain bacteria: nasal
epithelial cell ratio of 1:1 and 10:1. The results presented in
Table 1 show that bacteria exhibited high adherence (>50%)
to nasal cells. The adherence was more (73.7%) when
treated with higher number of bacterial cells i.e. 10:1. How-
ever, invasion of NEC was low, with only a maximum of
30% cells being invaded by the test bacteria. Similarly, cyto-
toxic damage inflicted by MRSA 43300 onto the cultured
NEC was very low with an estimated value of just 3.6% and
9% at bacteria: NEC ratio of 1:1 and 10:1 respectively.
Figure 2 Isolated murine nasal epithelial cells as observed under 40X Olympus light microscope on different days post-seeding. A)
and B) unstained and stained preparation of isolated single cells seen on the day of isolation C) unstained and D) stained preparation of cultured
NEC on day 2 post seeding. Nucleus is clearly evident in all the cells E) and F) cells as seen on day 3 post seeding of different shapes and sizes
and G) Polygonal shaped NEC as seen on day 5 with significant increase in size as well. These cells were harvested, counted and used for
adherence and invasion studies.
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and cytotoxicity of NEC
To demonstrate the effect of phage on the adherence
and consecutively invasion and cytotoxicity of NEC by
host bacteria, cultured NEC cells were processed in the
same way with bacteria added in a ratio of 10:1. Following
bacterial addition, phage was added at MOI-1 and MOI-
10. Cells were then incubated for allowing adherence and
invasion to occur.
From Table 1, it is evident that phage when added at
MOI-1 and MOI-10 to S. aureus 43300, was able to
significantly reduce (p < 0.05) all the three parameters
as compared to untreated control. Only 0.4% of the
bacterial cells showed adherence onto the nasal epithelial
cells in presence of phage added at MOI-1. At higher
MOI, adherence was reduced to negligible level. Similarly,
almost minimal invasion and cytotoxic damage to NECTable 1 Effect of phage on adhesion, invasion and cytotoxicit
Treatments Mean percent (%)
Adherence
Control (Bacteria + NEC;1:1) 58.6 ± 7.01
Control (Bacteria + NEC;10:1) 73.77 ± 7.8
Phage (MOI-1) 0.41 ± 0.202
Phage (MOI-10) 0.0258 ± 0.005was observed with phage added at MOI-1. At higher
phage concentration (MOI-10), the reduction in all the
three parameters was highly significant (p < 0.01) and no
invasion or cytotoxic damage was seen on NEC.
Table 2 depicts the adherence, invasion and cytotoxic
damage of five different clinical MRSA strains denoted as
CS-1 to CS-5(chosen at random) against which phage
(MR-10) showed lytic activity. S. aureus 29213(MSSA) was
also studied as an internal control. All the strains were
found to adhere to cultured nasal epithelial cells in signifi-
cant numbers (>60% adherence). The presence of phage
significantly affected the adherence of all the strains (p <
0.01). Maximum invasion (33%) and cytotoxicity (14%) was
observed with strain CS-3. The phage at MOI-1 was able
to sixgnificantly decrease both the invasion and cytotoxic
damage inflicted by all the clinical isolates. At higher MOI-
10, no detectable invasion or cytotoxicity was observed.y of NEC by S. aureus 43300
Invasion Cytotoxicity post 24 h
25 ± 3.73 3.6 ± 1.4
31.90 ± 1.34 11.1 ± 0.7
0.0307 ± 0.012 0.21 ± 0.035
No invasion No cytotoxicity

















S. aureus ATCC 43300 (MRSA) 73.7 0.41 0.025 31.9 0.031 No invasion 11.1 0.21 No cytotoxicity
S. aureus ATCC 29213 (MSSA) 76.8 0.51 0.034 18.4 0.034 No invasion 10.2 0.23 No cytotoxicity
S. aureus CS-1 68.4 0.37 0.066 28.1 0.06 No invasion 11.4 0.41 No cytotoxicity
S. aureus CS-2 62.5 0.32 0.074 25.4 0.064 No invasion 10.1 0.43 No cytotoxicity
S. aureus CS-3 74.8 0.45 0.084 33.3 0.078 No invasion 14.5 0.64 No cytotoxicity
S. aureus CS-4 70.4 0.34 0.081 30.4 0.072 No invasion 14 0.61 No cytotoxicity
S. aureus CS-5 72.1 0.33 0.075 32.8 0.066 No invasion 13.3 0.72 No cytotoxicity
(CS-1 to CS-5 : these are clinical strains (CS) of MRSA chosen at random to test for their adherence, invasion and cytotoxicity parameters on cultured murine NEC).
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The frequency of emergence of resistant colonies using
mupirocin was determined. The mupirocin resistant mu-
tants in vitro appeared at a frequency of (7.1 ± 0.54) × 10−6
and (2.4 ± 0.14) × 10−7 at 2 and 4 μg/ml (2X and 4X MIC)
respectively. The calculated bacteriophage insensitive
mutant (BIM) frequency at multiplicity of infection
(MOI) of 10 was comparatively higher with a value of
(7.4 ± 0.21) × 10−7. However, when both the agents
were used in combination, mutation rate was below
detection limit (<10−9). The results clearly depict the
advantage referred by combination treatment in decreas-
ing the frequency of resistant mutant generation.
Nasal colonisation model
A mouse model of nasal colonisation was established to
assess the potential of phage to decolonize the nares of
BALB/c mice from MRSA 43300. Three different inocu-
lum doses (105, 106 and 107 CFU/ml) of S. aureus 43300
were selected for establishing the organism in the nares
of BALB/c mice. The inoculum of 105 CFU/ml showed
persistence of the organism in the nares only till day 5
post colonisation and the organism was cleared there-
after. At an inoculum dose of 106 and 107 CFU/ml, S.
aureus 43300 persisted well till day 10 post colonisation
with a load of 3.98 log CFU/ml (106 CFU/ml) and 4.08
log CFU/ml (107 CFU/ml) respectively and no counts
observed on day 15 post colonisation. Since not much
difference in the bacterial load of S. aureus 43300 in
nares was observed with either of the two inoculum
doses, hence 106 CFU/ml was selected for establishing
the nasal colonisation with S. aureus 43300 (Data depict-
ing the nasal counts at all three different doses is shown
in Additional file 1: Table S3).
Bacterial load and phage titer
The nasal load of S. aureus 43300 on different days post
treatment is presented in Figure 3A. Mice administered
with phage twice (group 2) showed significant reduction(p < 0.01) of 2.8 log-cycles in bacterial counts on day 2
itself. This was followed by further decrease in counts
with 3.67 log CFU/g obtained on day 5 and minimal
load of 1.14 log CFU/g seen on day 7. The nares became
completely sterile as no growth of S. aureus 43300 was
observed beyond day 7. Similarly, mupirocin given once
(group 3) also showed significant reduction of ~2log
cycles in comparison to control (group 1) on day 2. On
day 7, minimal bacterial count of 2.21 log CFU/g was
obtained after which there was complete clearance of S.
aureus (Figure 3A).
The group receiving combined therapy (group 4) showed
maximum reduction in bacterial load in the anterior nares
with complete clearance of MRSA 43300 by day 5 itself
The bacterial load was significantly reduced (p < 0.05) to
5.17 log CFU/g (~3 log-cycles) on day 2 and this decrease
continued till day 3. By day 5, S. aureus 43300 was com-
pletely eradicated from the nasal tissue of BALB/c mice.
The combined treatment option gave maximum protection
against nasal colonisation by S. aureus 43300.
The animals receiving 2 doses of phage (107 PFU/ml
at an interval of 24 hours) showed a peak phage titre of
5.74 log PFU/g on day 2 (Figure 3B). Despite giving two
doses of phage (107 PFU/ml), only 105 PFU/ml was
present by day 2. A minimal phage titre (2.2 log PFU/g)
was seen on day 7 with no plaques visible thereafter. In
the co-therapy group, phage titres persisted only till day
3 (3.11 log PFU/g) and no plaque was seen on day 5.
Myeloperoxidase assay
MPO levels were highest in untreated S. aureus ATCC
43300 colonised (group 1) animals on all days as shown
in Figure 4. Peak MPO activity was seen on day 2 with
further decrease on subsequent days. However, MPO
levels were still higher on day 10 in this group than basal
MPO levels (0.608 ± 0.075 units/ml) detected in the nares
of normal healthy non-infected BALB/c mice (n = 3).
A significant reduction (p < 0.05) in MPO activity (as
compared to group 1) was seen in group 3 on all post-
Figure 3 Bacterial burden in terms of A) Mean log CFU/gram of mice tissue of S. aureus 43300 following treatment of colonised nares
with different anti-bacterial agents on different days post treatment; Phage counts in terms of B) Mean log PFU/g count in the anterior
nares of mice belonging to group 2 and group 4 on various days post phage treatment. Error bars represent the standard deviation.
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decrease in MPO levels with peak (1.44 units/ml) seen on
day 2 and 1.06 units/ml on day 3. By day 7, MPO levels
almost similar to basal values were achieved. The group
receiving combined therapy (group 4) showed minimal
MPO levels on all days. MPO activity of 0.71 units/ml
seen on day 2 accounted for a significant decrease of 69%
(p < 0.05) in comparison to group 1.
Histopathological examination
As seen in Figure 5A, the nasal tissue of colonised un-
treated animals (group 1) on day 2 post colonisation,
showed mild inflammation with recruitment of few acute
inflammatory cells seen in the epidermis which was com-
pressed by the collection of oedema fluids. Similarly, on day
5, the nasal mucosa of untreated colonised animals lined by
squamous epithelium showed marked sub epithelial inflam-mation rich in neutrophils and plasma cells (Figure 5B
and C). However, all the treated groups showed signifi-
cantly reduced signs of inflammation. The nasal mucosa
of phage treated group (group 2) (Figure 5D) on day 3
post treatment showed mild neutrophil and lymphoplas-
matic infiltration in the sub epithelial lining with skin
appearing nearly normal. Also, nasal mucosa of animals
treated with mupirocin (group 3) (Figure 5E), showed
small focus of mild inflammatory cells with skin appearing
nearly normal. Minimum tissue inflammation was seen in
nasal mucosa of animals receiving combined therapy
(group 5) (Figure 5F) with no inflammation and skin
appearing normal similar to nasal mucosa of healthy mice.
Discussion
Mupirocin is considered as the best topical antibiotic
available for gram positive bacteria [23,24] and has been
Figure 4 Mean MPO activity (Units/ml) detected in the homogenates of nares of different groups of mice on different days post treatment.
Red dotted line represent the basal MPO activity as seen in healthy BALB/c mice (n = 4). Error bars represent standard deviation.
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emergence of bacterial resistance to mupirocin is fast
rising leading to treatment failures and relapses [25-28].
In this study protection afforded by phage was therefore
compared with mupirocin treatment. In addition, the
additive effect if any, of the two agents as combination
therapy in reducing/eliminating MRSA colonisation was
also evaluated.
The first step in the colonisation by S. aureus is adher-
ence to nasal epithelial cells and mucous membrane via
bacterial cell surface moieties such as fibronectin binding
protein, teichoic acid and adhesins [29-35]. In this study,
the adherence and invasion pattern of MRSA 43300 on
nasal cells was evaluated. Cultured murine nasal epithelial
cells were used as substrates for studying the bacterial
adherence. MRSA 43300 showed high adherence of
58.6 ± 7.01 and 73.77 ± 7.8% when added at a multiplicity
of 1:1 and 10:1. The results confirmed the colonising
ability of S. aureus MRSA 43300 onto the mouse nasal
epithelium and its ability to survive in such cells for
longer time. Additional five clinical MRSA isolates tested
for their adherence ability also showed high adherence to
murine nasal cells ranging from 62% to 75%.S. aureus has the ability to invade the epithelial and
endothelial cells, osteoblasts, fibroblasts, and human
embryonic kidney cell lines [36-41]. These intracellular
reservoirs of S. aureus possibly protect the bacteria
from extracellular host defense mechanisms and anti-
microbial treatment instilled for their elimination. This
intracellular residency is now considered as one of the
reasons of possible long term nasal carriage and persistence
seen among chronic nasal carriers [40,42]. Invasion of the
epithelium by S. aureus and intracellular localisation of
bacteria in the nasal epithelial cells in vitro has been
demonstrated by Sachse et al. [43]. The presence of
heavily infected foci of intracellular S. aureus in nasal
epithelium cells was demonstrated by inverted confocal
laser scan fluorescence and electron microscopy [44]. This
was the first in vivo evidence of existence of internalized
S. aureus in nasal carriers. The invasion of S. aureus is
primarily promoted by fibronectin-binding proteins and
integrin-mediated invasion of S. aureus into nonprofessional
phagocytes has also been demonstrated [36-39,45-48].
The ability of MRSA 43300 to invade the nasal epithelial
cells in this study is supported by the fact that S. aureus
ATCC 43300 posesses the fnbB gene which mediates
Figure 5 Histopathological analysis showing. A) Photo micrograph of skin tissue of nasal mucosa of untreated colonised mice on day 2 post
colonisation showing mild inflammation with recruitment of few acute inflammatory cells(red arrows) (H and E 100X). B) and C) Photo micrograph of
skin tissue of nasal mucosa of untreated colonised mice on day 5 post colonisation showing marked sub epithelial inflammation rich in neutrophils
and plasma cells (H and E 100X and 200X). D) and E) Photo micrograph of skin tissue of nasal mucosa of phage treated (group 3) and Mupirocin
treated(group 4) mice on day 5 post treatment showing mild infiltration in the sub epithelial lining (H and E 100X). F) Photo micrograph of skin tissue
of nasal mucosa of mice receiving combined therapy (group 5) with nearly normal skin (H and E 100X).
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http://www.biomedcentral.com/1471-2180/14/212invasion and thus 30% of the adhered population invaded
the nasal epithelial cells. Cytotoxicity data revealed that
this strain inflicted low(<10%) cytotoxicity post 24 hours of
adherence. These results suggest that the bacteria posed
little damage to the epithelial cells which infact may be
beneficial for their long term survival within the host tissue.
The effect of phage on the adherence and invasion
pattern of MRSA 43300 was determined using thein vitro model of cultured murine nasal epithelial cells.
Phage at both the MOI (1, 10) was able to show highly
significant reduction in all the three parameters as com-
pared to untreated control. A pronounced decrease in the
number of adhered bacterial population with negligible
invasion and cytotoxicity was observed. Similarly phage
was also able to significantly affect all the three parameters
in clinical MRSA strains tested for these properties
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with the findings of Clem [49] who showed that bacterio-
phages had protective effect on HEp-G2 cells from cellular
damage and apoptosis induced by MRSA isolates.
A combination therapy with antimicrobials differing in
their mechanisms of action has been suggested to treat
infections. This approach not only provides a broad
spectrum of action due to synergistic effect but it also
helps in preventing the emergence of drug-resistant sub-
population. It has been proposed that bacteria acquiring
simultaneous resistance to both the phage and antibiotic
is remote [13,14,50]. The results of this study suggest that
when used in combination with phage, the frequency of
emergence of spontaneous mutants towards mupirocin
was effectively decreased to negligible levels (<10−9).
To the best of our knowledge, the efficacy of lytic
phage in decolonising the nares in an animal model has
not been evaluated, though, the efficacy of phage born
lytic enzymes has been assessed [51-53]. Hence, for
assessing the therapeutic potential of phage MR-10 and
mupirocin in eliminating the nasal carriage of MRSA
43300, acute nasal colonization model (10 day) was experi-
mentally established in healthy male BALB/c mice. MRSA
colonisation was accomplished by putting a stress on the
resident flora by increasing the inoculum load (106 CFU/
ml, given twice) which helped in the dominance of MRSA
43300 in the nasal tissue over the resident flora. The
treatment was started after allowing the bacteria to
colonise the nasal tissue of mice (in a period of 48 hours)
in order to mimic the scenario prevalent in hospital and
community settings, where the treatment is initiated in an
already colonised person. Mice receiving two doses of
phage MR-10 showed significant reduction (2.8 log cycles)
on day 2 itself. Similarly, mupirocin given at a dose of
5 mg/kg (group 3) also showed significant reduction of
2 log cycles on day 2 and minimal bacterial load of 2.2
log CFU/gram on day 7. Both the agents given alone
were able to significantly decrease the nasal load of
MRSA 43300 by day 7. On the other hand, the group
receiving the combined therapy, showed complete clear-
ance of MRSA 43300 in a shorter period of time i.e. by
day 5 itself. Also the decrease in bacterial load was
significantly greater than the monotherapy groups
(group 2 and 3) on all days. Also peak phage titres were
observed on day 2 and declined thereafter. In the co-
therapy group, phage titres persisted till day 3 only and
no plaque was seen on day 5. As phages are highly
specific and thus replicate and increase in number at
the expense of their respective host bacteria [53,54]
hence no phage activity observed on different days, points
towards complete eradication of their host bacteria
(MRSA 43300) following treatment with phage. Com-
plete eradication of bacteria was possible due to the
combined administration of two agents after allowingsuccessful colonisation of the bacteria in the nasal tissue
of mice.
The presence of S. aureus in the nose elicits a subclinical
immune response, as reported in an earlier study where
sero-conversion occurred after carriage was established
[55]. Also the host elicits a number of immune factors
that constantly impose pressure to eliminate the foreign
colonising population [34,56]. Neutrophils are the most
prominent cellular component of the innate immune
system and act as an essential primary defence against
S. aureus [57]. In this study, neutrophil recruitment
was studied in terms of MPO levels in all the groups.
MPO levels were highest in the untreated colonised
group on all post treatment days. The groups receiving
phage and mupirocin alone showed peak MPO levels
on day 2 and the activity declined to the basal value by
day 7. This observation correlates well with the declining
bacterial load seen on day 7 in both these groups. Combin-
ation therapy group exhibited maximum reduction in MPO
levels on day 2 onwards. These results further confirm the
efficacy of phages in eliminating the colonized S. aureus
from the anterior nares of mice. The results of histopatho-
logical examination of control (untreated) and treated nasal
tissue also substantiated these observations. In the com-
bined therapy group, minimal or no tissue infiltration was
seen and the skin of nasal mucosa appeared normal.
The present study indicates that the phage when given
along with mupirocin was able to effectively eradicate
the colonising population due to their combined action.
The dual approach showed maximum nasal protection
(better than use of either agent alone i.e. monotherapy)
in terms of reduced nasal bacterial load, reduced catalase
and MPO levels; with complete elimination of MRSA
43300 occurring by day 5. Coates et al. [35] advocated the
need to develop potent bactericidal agent than mupirocin
on the ground that the newer agents might reduce the
relapse rate, clearing the patient of S. aureus for a longer
period of time than mupirocin. The success obtained with
this dual approach is based on the fact that mupirocin
being a bacteriostatic antibiotic was able to significantly
halt the multiplication and growth of S. aureus which was
then easily eliminated and cleared off by the lytic phages.
Conclusion
The present study provides insights into the use of dual
therapy for effective decolonisation of MRSA in lesser
period of time with reduced chances of relapse and
emergence of resistant mutants. In the present study,
use of single phage for nasal decolonisation has been
looked into, however, for this approach to be successful
in clinical settings, need to study a cocktail of phages
covering a larger spectrum of strains is required. Also,
different delivery systems to achieve a sustained release
of the phages may also be investigated.
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